齐雷索韦
![]() | |
临床资料 | |
---|---|
商品名 | Ziresovir |
法律规范状态 | |
法律规范 |
|
识别信息 | |
| |
CAS号 | 1422500-60-4 |
PubChem CID | |
ChemSpider | |
UNII | |
化学信息 | |
化学式 | C22H25N5O3S |
摩尔质量 | 439.5 |
3D模型(JSmol) | |
| |
|
齐雷索韦(ziresovir、RO-0529、AK0529,化学式C22H25N5O3S)是一种抗病毒药,被开发用于治疗呼吸道合胞病毒感染。它作为一种融合抑制剂,在II期临床试验中显示出较好的疗效。[1][2]
参见
参考文献
- ^ Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, Feng S, Zhang B, Zhou M, Yu X, Xiang K, Chen L, Guo T, Shen HC, Zou G, Wu JZ, Yun H. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor. J Med Chem. 2019 Jul 11;62(13):6003-6014. doi:10.1021/acs.jmedchem.9b00654 PMID 31194544
- ^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. PMID 30974127 doi:10.1016/j.antiviral.2019.04.006